Enzymlogic presents its Binding Kinetics Platform at 18th Drug Discovery Summit
Jun, 12-13th 2017
A Binding Kinetics Platform that boosts the understanding of drug efficacy in vivo.
As the kickoff to the 18th Drug Discovery Summit in Berlin, Germany on June 12th approaches, the Enzymlogic team is becoming increasingly excited. We are proud to be a sponsor of this two-day event that will explore a broad range of topics about drug discovery and medicinal chemistry.
Ana Corrionero, CEO of Enzymlogic, will be presenting a talk entitled “Dynamism and specificity: The value of Binding Kinetics and Kinetic Selectivity to discover effective medicines”. The presentation will take place on Tuesday, June 13, 09:30 am (CET). Don’t miss the opportunity to join us and learn how our Binding Kinetics Platform can bring you and your business great competitive advantage.
We are pleased to come back as exhibitor to the Drug Discovery Summit. This event allows us to introduce to the global pharmaceutical community our most relevant innovations. Our Binding Kinetics Platform guides the kinetic optimization of drug candidates and accelerates the drug discovery process by withdrawing ineffective or unsafe molecules earlier in the drug discovery process said Ana Corrionero, CEO at Enzymlogic.
Enzymlogic offers in vitro biochemical and cell-based assays to the biotechnological and pharmaceutical companies, life science laboratories and academic groups. Our binding kinetics, kinetic selectivity, assay development, profiling and screening services enable faster and cost-effective drug discovery by identifying the most promising drug candidates as well as withdrawing those compounds likely to fail in pre-clinical development. Additionally, Enzymlogic’s pioneering approach provides predictive tools that deliver physiologically relevant insights earlier in the drug discovery process.
About 18th Drug Discovery Summit
This event will gather over 250 delegates representing leading biotech companies, global pharmaceutical organisations and internationally renowned academic institutions, and will feature 55 presentations, case studies and panel discussions focused on the key issues in drug discovery and medicinal chemistry. The 18th Drug Discovery Summit is co-located with 5th Annual Discovery Chemistry and Drug Design Congress as well as an inaugural edition of Microbiome Discovery and Development Congress.Back